A protective and broadly cross-neutralizing epitope of human papillomavirus L2

Ratish Gambhira, Balasubramanyam Karanam, Subhashini Jagu, Jeffrey N. Roberts, Christopher B. Buck, Ioannis Bossis, Hannah Alphs, Timothy Culp, Neil D. Christensen, Richard B.S. Roden

Research output: Contribution to journalArticlepeer-review

178 Scopus citations


We generated a monoclonal antibody, RG-1, that binds to highly conserved L2 residues 17 to 36 and neutralizes human papillomavirus 16 (HPV16) and HPV18. Passive immunotherapy with RG-1 was protective in mice. Antiserum to the HPV16 L2 peptide comprising residues 17 to 36 (peptide 17-36) neutralized pseudoviruses HPV5, HPV6, HPV16, HPV18, HPV31, HPV 45, HPV 52, HPV 58, bovine papillomavirus 1, and HPV11 native virions. Depletion of HPV16 L2 peptide 17-36-reactive antibodies from cross-neutralizing rabbit and human L2-specific sera abolished cross-neutralization and drastically reduced neutralization of the cognate type. This cross-neutralization of diverse HPVs associated with cervical cancer, genital warts, and epidermodysplasia verruciformis suggests the possibility of a broadly protective, peptide-based vaccine.

Original languageEnglish (US)
Pages (from-to)13927-13931
Number of pages5
JournalJournal of virology
Issue number24
StatePublished - Dec 2007

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology


Dive into the research topics of 'A protective and broadly cross-neutralizing epitope of human papillomavirus L2'. Together they form a unique fingerprint.

Cite this